(American Association for Cancer Research) Bacterial load was significantly higher in pancreatic tumor samples from patients with pancreatic ductal adenocarcinoma compared with pancreatic tissue from normal individuals, and in studies using mice, eliminating certain ‘bad’ bacteria slowed the growth of pancreatic cancer, reversed immune suppression, and upregulated the immune checkpoint protein PD1.

Related Links:

ConclusionOur study is the first to show that miR-125a-3p is responsible for chemosensitivity in PDAC and could inhibit epithelial-mesenchymal transition by directly targeting Fyn. This provides a novel potential therapeutic strategy to overcome chemoresistance in PDAC.Graphical abstract

No abstract available

Source: Annals of SurgeryCategory: Surgery Tags: Letters and Responses Source Type: research

This article reviews the literature available regarding the management of the so-called frail patients and provide guidance for chemotherapy as well as supportive care treatments.

Authors: Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Yamada Y, Arai T, Kita Y, Kijima Y, Mataki Y, Maemura K, Natsugoe S
Abstract
MicroRNAs (miRNAs) are unique in that a single miRNA molecule regulates a vast number of RNA transcripts. Thus, aberrantly expressed miRNAs disrupt tightly controlled RNA networks in cancer cells. Our functional screening showed that expression of miR-124-3p was downregulated in pancreatic ductal adenocarcinoma (PDAC) tissues. Here, we aimed to investigate the anti-tumor roles of miR-124-3p in PDAC cells and to identify miR-124-3p-mediated oncogenic signaling in this…

Source: OncotargetCategory: Cancer & Oncology Tags: Oncotarget Source Type: research

ConclusionCombination of systemic chemotherapy and oligometastasectomy with adjunctive local IRE therapy is a feasible treatment strategy in highly select patients with oligometastatic PDAC that demonstrate favorable tumor biology with objective response to systemic therapy.

Publication date: September 2018Source: Clinica Chimica Acta, Volume 484Author(s): Song Mao, Xiaopeng Wang, Liangxia Wu, Dou Zang, Wenjing ShiAbstractBackgroundWe assessed the association between tissue klotho protein expression and the risk and progression of malignancies.MethodsWe searched the electronic databases for the studies regarding the relationship between tissue klotho protein expression and risk/progression of malignancies through January 2018. We calculated the pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) to evaluate the impact of tissue klotho protein expression on malignancies. A…

In conclusion, our results suggest that miR-1297 inhibits the growth and metastasis of pancreatic adenocarcinoma by downregulating MTDH expression, and the miR-1297/MTDH pathway is a potential target for treating pancreatic adenocarcinoma.

Publication date: Available online 28 June 2018Source: Advances in Biological RegulationAuthor(s): Stephen L. Abrams, Kvin Lertpiriyapong, Li V. Yang, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Marco Falasca, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Linda S. Steelman, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are read…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Saverio Candido, Stephen L. Abrams, Linda Steelman, Kvin Lertpiriyapong, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Matilde Y. Follo, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak, Dariusz Rakus, Pann-Gill Suh, Massimo Libra, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagn…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco FalascaAbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, em…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image